Last Updated: November 16, 2026

Inebilizumab-cdon - Biologic Drug Details

« Back to Dashboard


Summary for inebilizumab-cdon
Tradenames:1
High Confidence Patents:0
Applicants:1
BLAs:1
Suppliers: see list1
Pharmacology for inebilizumab-cdon
Mechanism of ActionCD19-directed Antibody Interactions
Established Pharmacologic ClassCD19-directed Cytolytic Antibody
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. DrugPatentWatch analysis and brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for inebilizumab-cdon Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for inebilizumab-cdon Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for inebilizumab-cdon Derived from Patent Text Search

No patents found based on company disclosures

Inebilizumab-cdon Market Dynamics, Revenue Outlook, Patent Protection, and Competitive Position

Last updated: September 15, 2026

Inebilizumab-cdon, marketed as Uplizna, is a CD19-directed B-cell-depleting biologic owned by Amgen following its acquisition of Horizon Therapeutics. The drug was FDA-approved in 2020 for adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder, or AQP4-positive NMOSD. Its commercial trajectory depends on three factors: expansion beyond a rare neurological indication, durable biologic exclusivity through 2032, and competition from complement inhibitors, IL-6 pathway drugs, and off-label rituximab.

Uplizna has a high-value orphan-drug profile. Its small treated population limits volume, but chronic administration, specialist prescribing, and a high annual list price support significant revenue per patient.

What is inebilizumab-cdon and how does Uplizna work?

Inebilizumab-cdon is a humanized monoclonal antibody targeting CD19, a B-cell surface antigen expressed across a broader range of B-cell development than CD20. The drug depletes B cells through antibody-dependent cellular cytotoxicity.

The FDA-approved regimen for NMOSD is:

Treatment phase Dose
Initial infusion 300 mg intravenously
Second infusion 300 mg two weeks later
Maintenance 300 mg every six months

The approved population is adults who are anti-AQP4 antibody positive. The label is narrower than the total NMOSD market because AQP4-negative patients are not included in the approved indication.[1]

The commercial value of inebilizumab comes from continued maintenance dosing. A patient who remains on therapy generates recurring treatment revenue approximately twice per year, subject to insurance coverage, discontinuation, adverse events, and switching.

What FDA approvals and regulatory milestones affect inebilizumab-cdon?

Date Regulatory or corporate milestone
June 11, 2020 FDA approved Uplizna for adults with AQP4-positive NMOSD
2020 U.S. commercial launch by Viela Bio
March 2021 Horizon Therapeutics completed acquisition of Viela Bio
October 2022 European Commission authorized Uplizna for adult patients with AQP4-positive NMOSD
October 2023 Amgen completed its acquisition of Horizon Therapeutics
2023-2024 Development continued in generalized myasthenia gravis and IgG4-related disease

The pivotal N-MOmentum study reported a substantial reduction in NMOSD attack risk compared with placebo. FDA labeling describes a 73% reduction in the risk of an NMOSD attack in the randomized controlled period.[1,2]

The regulatory expansion strategy is commercially important because NMOSD is a rare disease with a limited treated population. Generalized myasthenia gravis, or gMG, has a substantially larger addressable population and includes established biologic competitors. IgG4-related disease is another expansion opportunity, although its commercial value depends on eventual labeling, clinical differentiation, and payer adoption.

When does inebilizumab-cdon lose biologic exclusivity?

The key U.S. exclusivity date is June 11, 2032, representing 12 years of reference-product exclusivity from the original FDA approval date under the Biologics Price Competition and Innovation Act.[3]

Protection category U.S. position
Reference biologic approval June 11, 2020
FDA biologic exclusivity Through approximately June 11, 2032
Biosimilar pathway 351(k) application
Orange Book listing Not applicable
Purple Book status Reference biological product
Generic Paragraph IV filing Not applicable
Biosimilar litigation risk Potentially begins before commercial entry, subject to patent and regulatory timing

Biologic exclusivity does not eliminate patent risk. Amgen can assert formulation, manufacturing, dosing, method-of-use, or other patents against a biosimilar applicant. Conversely, a biosimilar sponsor can challenge patents before the statutory exclusivity period ends, depending on the application and litigation strategy.

The absence of Orange Book listings is material. Uplizna is regulated as a biologic, so the relevant reference-product and biosimilar framework is the FDA Purple Book and the BPCIA, not the Hatch-Waxman Paragraph IV process used for small-molecule drugs.[3,4]

What patents protect Uplizna and inebilizumab-cdon?

Public commercial analysis should distinguish three layers of protection:

  1. FDA biologic exclusivity through 2032.
  2. Patent protection covering the antibody, its sequence, production, formulation, dosing, or use.
  3. Practical manufacturing know-how that may be difficult to replicate even after patent expiry.

A complete patent-by-patent freedom-to-operate analysis requires a current claim chart across U.S., European, and other national registers. The publicly visible commercial protection is therefore best assessed by category rather than by treating any single patent as the entire estate.

What formulation patents protect inebilizumab-cdon?

Formulation claims can cover:

  • Concentration of inebilizumab.
  • Buffer composition and pH.
  • Stabilizing excipients.
  • Container or delivery conditions.
  • Storage and infusion preparation.

Formulation patents can delay a biosimilar that uses the same composition, but they usually do not prevent all non-infringing formulations. Their commercial impact depends on claim breadth, patent term, prosecution history, and whether the biosimilar can redesign its formulation without affecting stability or administration.

What method-of-use patents protect Uplizna?

Potential method-of-use protection can cover:

  • Treating AQP4-positive NMOSD.
  • Reducing NMOSD attacks.
  • Maintenance dosing at six-month intervals.
  • Treating additional B-cell-mediated autoimmune diseases.
  • Patient selection based on biomarker or disease characteristics.

Method-of-use patents are more valuable when the label and standard clinical practice require the patented regimen. Their enforcement becomes more difficult when physicians prescribe a biosimilar for an unpatented use or when the biosimilar label omits protected indications.

What manufacturing barriers affect biosimilar entry?

Inebilizumab is a complex antibody product. A biosimilar developer must demonstrate analytical similarity, process control, pharmacokinetic comparability, immunogenicity performance, and clinical or comparative evidence required by FDA. Manufacturing barriers include:

  • Cell-line development.
  • Control of glycosylation and other critical quality attributes.
  • Viral clearance and process validation.
  • Comparability after manufacturing changes.
  • Commercial-scale sterile filling.
  • Consistent supply for an infusion product.

These barriers do not create legal exclusivity, but they raise development cost and can reduce the number of early biosimilar entrants.

How strong is the commercial patent estate for Uplizna?

The estate is commercially strong through 2032 because biologic exclusivity protects the reference product before patent disputes become the primary entry issue. After 2032, strength will depend on the duration and enforceability of later-expiring patents.

The strongest potential protection is likely to come from patents that combine:

  • A clinically validated dosing schedule.
  • A narrow but unavoidable approved use.
  • A formulation used in the commercial product.
  • Manufacturing claims that are difficult to design around.

The weakest protection would be a narrow method-of-use claim where physicians can prescribe a competing biologic for the same disease under a different indication or dosing regimen.

What is the financial trajectory for inebilizumab-cdon?

Uplizna has progressed from an early-stage orphan launch to a strategic growth asset inside Amgen’s Horizon portfolio. The financial profile has four defining characteristics:

Financial driver Effect on Uplizna
High annual treatment cost Supports substantial revenue per patient
Rare-disease population Limits total patient volume
Six-month maintenance dosing Creates recurring revenue
Label expansion potential Determines whether the product remains a niche asset or becomes a broader immunology franchise

U.S. pricing has been reported at approximately $163,000 in annual wholesale acquisition cost, although net realized revenue is lower after rebates, discounts, patient assistance, and payer concessions.[5] Actual revenue also varies with treatment persistence and the share of patients administered in hospital or outpatient settings.

The acquisition history shows the strategic value assigned to the asset. Horizon acquired Viela Bio in 2021 for approximately $3.0 billion, and Amgen acquired Horizon in a transaction valued at approximately $27.8 billion in 2023.[6,7] Those transactions included broader portfolios, so they should not be interpreted as standalone valuations for Uplizna.

The base-case financial trajectory is:

  • Near term: continued NMOSD growth through increased diagnosis, specialist adoption, and persistence.
  • Medium term: revenue acceleration if gMG or IgG4-related disease approvals are obtained.
  • Long term: pricing and volume pressure as biosimilar competition becomes feasible after regulatory and patent barriers decline.

The principal financial risk is indication concentration. If Uplizna remains limited to AQP4-positive NMOSD, the product can generate durable specialty revenue but is unlikely to achieve the scale of broad immunology biologics. An approved gMG indication would expand the addressable population but place Uplizna against Vyvgart, Vyvgart Hytrulo, Rystiggo, Soliris, Ultomiris, and rituximab.

Which companies are challenging inebilizumab-cdon?

No conventional generic can enter because inebilizumab is a biologic. The relevant future competitors are biosimilar developers and branded biologic manufacturers.

Potential competitive groups include:

  • Large biosimilar manufacturers such as Sandoz, Biocon Biologics, Celltrion, Samsung Bioepis, and Amgen’s own biosimilar organization.
  • NMOSD competitors, including Roche’s satralizumab and Alexion’s eculizumab and ravulizumab.
  • Off-label rituximab, which remains widely used because of familiarity, lower cost, and extensive clinical experience.
  • Emerging B-cell depletion and autoimmune therapies targeting adjacent mechanisms.

There is no established public evidence of a commercially launched inebilizumab biosimilar. Entry before 2032 would face the FDA’s reference-product exclusivity and any enforceable patent claims.

How does Uplizna compare with competing NMOSD drugs?

Product Mechanism Administration Main commercial advantage
Uplizna CD19 B-cell depletion IV every six months after loading Infrequent maintenance dosing
Enspryng IL-6 receptor inhibition Subcutaneous At-home administration
Soliris Complement C5 inhibition IV every two weeks Established efficacy and broad experience
Ultomiris Long-acting C5 inhibition IV at extended intervals Longer dosing interval than Soliris
Rituximab CD20 B-cell depletion IV, off-label in NMOSD Lower cost and extensive use

Uplizna’s clinical differentiation is the depth of B-cell targeting and twice-yearly maintenance treatment. Its disadvantages include infusion-center dependence, immunosuppression risks, high acquisition cost, and competition from self-administered therapies.

What litigation and settlement risks affect Uplizna?

A conventional Paragraph IV litigation pathway does not apply. Future disputes would more likely involve:

  • BPCIA patent-exchange procedures.
  • Declaratory-judgment actions.
  • Patent infringement claims covering manufacturing or formulation.
  • Licensing agreements with biosimilar developers.
  • Patent settlements that specify delayed entry dates.

No major public U.S. settlement involving an inebilizumab biosimilar has established an entry date. The absence of a settlement means the commercial entry timetable remains controlled by biologic exclusivity, patent validity, patent scope, and biosimilar development progress.

What geographic markets matter for inebilizumab-cdon?

The United States is the principal value market because of high biologic reimbursement and specialist concentration. Europe provides broader geographic reach but generally imposes greater pricing pressure through centralized or national reimbursement negotiations.

Key market variables by region include:

Region Main issue
United States High price, specialty pharmacy and infusion reimbursement, biologic exclusivity
European Union Country-level health technology assessment and price negotiation
Japan Reimbursement listing and post-approval surveillance
Canada Provincial reimbursement and rare-disease funding
Emerging markets Lower price, limited specialist access, and infusion infrastructure

The product’s administration requirements favor health systems with established neurology infusion networks. Limited diagnostic access for AQP4 antibodies can delay treatment initiation in lower-resource markets.

What generic launch scenarios exist for Uplizna?

Scenario 1: No biosimilar before 2032

This is the most straightforward scenario. Amgen retains reference-product pricing power, subject to payer pressure and branded competition.

Scenario 2: Patent challenge before 2032, delayed entry

A biosimilar sponsor challenges selected patents but accepts an entry date after settlement. Amgen preserves most exclusivity while reducing litigation uncertainty.

Scenario 3: First biosimilar entry after 2032

Price erosion develops gradually. The impact depends on the number of entrants, interchangeability status, payer contracting, and whether physicians view biosimilars as equivalent for NMOSD.

Scenario 4: Label expansion before biosimilar entry

A new gMG or IgG4-related disease indication increases patient exposure and revenue before competition arrives. This is the highest-upside commercial path.

Key Takeaways

  • Inebilizumab-cdon is marketed as Uplizna and owned by Amgen through its Horizon acquisition.
  • FDA approval occurred on June 11, 2020, for adults with AQP4-positive NMOSD.
  • U.S. biologic exclusivity runs approximately through June 11, 2032.
  • Orange Book Paragraph IV litigation does not apply; future competition will use the BPCIA biosimilar framework.
  • Uplizna’s commercial strengths are six-month dosing, specialist use, and high revenue per treated patient.
  • Its principal limitation is the small NMOSD population unless FDA approves additional indications.
  • The main branded threats are satralizumab, eculizumab, ravulizumab, newer myasthenia gravis therapies, and off-label rituximab.
  • The largest financial catalyst is expansion into gMG or IgG4-related disease.
  • The largest long-term risk is biosimilar entry after biologic exclusivity and patent protection decline.

FAQs

Is inebilizumab-cdon a biosimilar or a reference biologic?

Inebilizumab-cdon is the active ingredient in Uplizna and is the reference biologic approved by FDA. It is not a biosimilar.

Does Uplizna have an Orange Book patent listing?

No. Biologics such as Uplizna are tracked under the FDA Purple Book and the BPCIA rather than through Orange Book listings.

What is the annual cost of Uplizna?

The reported U.S. wholesale acquisition cost is approximately $163,000 per year before rebates, discounts, assistance programs, and payer adjustments.

Can rituximab replace inebilizumab-cdon?

Rituximab is used off-label in NMOSD and may be less expensive, but it is not an FDA-approved substitute for Uplizna in AQP4-positive NMOSD.

What would most increase Uplizna revenue?

FDA approval in a larger autoimmune population, particularly generalized myasthenia gravis, would have the greatest potential to expand Uplizna’s treated population and revenue base.

References

  1. U.S. Food and Drug Administration. (2020). Uplizna (inebilizumab-cdon) prescribing information.
  2. Cree, B. A. C., Bennett, J. L., Kim, H. J., et al. (2019). Inebilizumab for the treatment of neuromyelitis optica spectrum disorder. New England Journal of Medicine, 381, 1280-1291.
  3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
  4. U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Public Law 111-148.
  5. Horizon Therapeutics plc. (2022). Annual report and Form 10-K.
  6. Horizon Therapeutics plc. (2021). Horizon Therapeutics completes acquisition of Viela Bio.
  7. Amgen Inc. (2023). Amgen completes acquisition of Horizon Therapeutics.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.